Shares of Biocon Ltd. rose 1.45% in intraday trade to Rs 370.06 apiece after the company announced the launch of Everolimus tablets, a generic version of Afinitor in the U.S., thereby expanding its generic formulations portfolio.
- MCX Silver Target Price Hit Low 67441 | Neal Bhai
- Gold MCX Full Target Done – Silver SL Hit – Neal Bhai Reports
- Maruti Suzuki Expects Chip Shortage To Adversely Impact October Production In Haryana & Gujarat
- BLS International Wins Embassy Of Italy Contract To Process Visa Applications In Russia For Five Years
- Dilip Buildcon is required to pay a penalty of Rs 3 crore with NHAI
Everolimus tablets, a prescription drug used to treat certain types of cancers, have been introduced in four doses. According to IQVIA, U.S. sales of Everolimus tablets was approximately $675 million in the 12 months ending July 2021.
सोशल मीडिया अपडेट्स के लिए हमें Facebook ( https://www.facebook.com/goldsilverreports/ ) और Twitter ( https://twitter.com/goldsilverrepor ) पर फॉलो करें।
हमारी फ्री सर्विस और लोगो की paid सर्विस से कई गुना अच्छी है।
आपको हर दिन दिए जाएंगे 3 से 5 कॉल बिलकुल फ्री
हर CALL में PROFIT दिये जायेंगे
EQUITY CHANNEL को JOIN कर लो (EQUITY FREE TIPS)
JOIN US CLICK HERE
Of the 22 analysts tracking the company, 11 maintained ‘buy’, five maintained ‘hold’ and six maintained ‘sell’ recommendations. The overall consensus price of analysts tracked by Bloomberg implied an upside of 8.3%.
| Follow us on |
| Telegram, Whatsapp , Facebook, Twitter, Instagram, YouTube, Google Business Profile and Truth Social. |